Treatment with linagliptin reduced the progression of albuminuria but had no effect on death due to renal failure, ESRD, or sustained 40% or higher decrease in eGFR from baseline (269)
Medication orders lacking structured information on total days supplied were excluded, as these were frequently free-text entries unsuitable for reliable longitudinal analysis
It is currently accessible only to participants enrolled in clinical trials
This means that the man-made active ingredient semaglutide, tirzepatide, or liraglutide binds to the same receptors
It can also cause increased pain, bruising, bleeding, and the formation of hard lumps under the skin
Each participant receives a plan formulated by licensed physicians, ensuring optimal dosing and ongoing review